BharatBriefly
Read less. Ask more.

Intelligent News Feed

Loading…

Novartis Raises Peak Sales Forecast to $18 Billion Ahead of Capital Markets Day

· Business · CNBC, Reuters

Swiss pharmaceutical giant Novartis upgraded its peak sales forecast for three key blockbuster drugs to a combined $18 billion ahead of its Capital Markets Day. The revised estimate covers multiple sclerosis treatment Kesimpta, leukaemia drug Scemblix, and cholesterol medicine Leqvio, surpassing its previous combined projection of $14 billion. The company simultaneously projected annual sales growth of 5% through 2031, adjusting its previous guidance of 5% to 6% through 2030. CEO Vas Narasimhan stated the new forecast accounts for expected generic competition in the United States for its breast cancer treatment Kisqali by the second half of 2031. Following the announcement, Novartis shares fell 2.4% in morning trading in Switzerland.

Why it matters

Investors and healthcare markets evaluate whether Novartis can offset impending patent expiries on older blockbuster drugs with robust sales from newer treatments.

Read the original report — CNBC

Join us on Telegram
Breaking news the moment it lands. At 10,000 members we ship the Android app.